Copyright © 2025 Shenyang Dasan Pharmaceutical Technology Co., Ltd.
Home

A Must-Save! The 4 Stages of Gout: How to Achieve Long-Term Management and Prevent Recurrence? A Lancet Article Explains Clearly

Posting Date：2021-04-28Views：
以下是保留原 HTML 结构的翻译结果： --- ```html
Gout is a common chronic disease. Data from studies in Asia, Europe, and North America show an adult prevalence ranging from 0.68% to 3.90%. Gout is more prevalent in men, with Asian studies reporting a male-to-female ratio of approximately 8:1. However, the management of gout is generally suboptimal, with many patients experiencing recurrent flares and not receiving standard urate-lowering therapy.
 

Elevated serum urate concentration is the most important risk factor for the development of gout, and long-term reduction of urate levels to reverse hyperuricemia is the main strategy for effective gout management. How to manage acute gout flares, what are the key considerations for long-term management, and how can recurrence be prevented? A recent review article published in The Lancet provides a comprehensive overview of the latest advances in the clinical features, pathophysiology, and treatment of gout.

 

 

▉Four Pathophysiological Stages: Hyperuricemia ≠ Gout

 

The progression of hyperuricemia and gout involves four pathophysiological stages: the development of hyperuricemia, the deposition of urate crystals, gout flares triggered by acute inflammatory responses to deposited crystals, and the advanced stage characterized by tophi. Some patients may progress to the advanced stage without ever experiencing a gout flare.

 
Hyperuricemia is a necessary step in the development of gout. Urate is the end product of purine nucleotide degradation. High-purine diets or other dietary factors (such as alcohol and fructose intake) that promote purine nucleotide degradation increase serum urate levels and the risk of gout. Conditions such as psoriasis and myelodysplastic syndromes can also raise serum urate concentrations. Urate excretion is regulated by the kidneys and intestines, and impaired urate excretion increases serum urate levels. Elevated circulating insulin concentrations (in the setting of high body mass index and metabolic syndrome) and diuretics can also reduce renal urate excretion.
 
Most individuals with hyperuricemia are asymptomatic and do not develop gout. Even among those with severe hyperuricemia (≥600 μmol/L; approximately 10 mg/dL), fewer than half develop gout within 15 years.
 
The presence of urate crystal deposition in individuals with hyperuricemia is considered a key milestone in the development of gout. Approximately 25% of individuals with hyperuricemia have urate crystal deposition, which can be confirmed through imaging.
 
The activation of the NLRP3 inflammasome in macrophages and monocytes by urate crystals is particularly associated with gout flares. Activation of the NLRP3 inflammasome depends on two signals, and the inflammatory response triggered by urate crystals is only one step, which explains why early urate deposition may not be accompanied by obvious clinical inflammation.
 

Tophi represent the body's chronic, foreign-body granulomatous inflammatory response to urate crystals.

 

▉Clinical Manifestations Go Beyond Gout Flares

 

The classic initial presentation of gout is a gout flare—an acutely painful inflammatory arthritis that primarily affects the joints of the lower extremities (feet, ankles, and knees). Flares can also occur in the elbows, wrists, and hands, but upper extremity involvement is typically seen only in patients with long-standing, poorly controlled disease. Gout flares are usually monoarticular; polyarticular flares typically occur in patients with poorly controlled disease and may be accompanied by significant systemic symptoms, including fever, chills, and even delirium.

 

 

▲Gout flares primarily affect joints of the lower extremities

The time from flare onset to peak pain is usually less than 12 hours, accompanied by varying degrees of redness and swelling, which may limit mobility and make walking difficult.
 
Without treatment, gout flares typically resolve within 7–14 days, followed by a pain-free period before another flare occurs. Recurrence of gout is often unpredictable but is associated with the severity of hyperuricemia. Triggers for gout flares include high-purine foods, alcohol intake, joint trauma, and acute illness. Most patients experience recurrent flares, and with sustained exposure to higher serum urate levels and increasing urate burden, each flare may last longer.
 
Over time, some individuals with persistent hyperuricemia may develop tophi, chronic gouty arthritis, and structural joint damage. Common locations for tophi include the joints, ears, bursae, fingertips, and tendons. Tophi can vary greatly in size; they are usually firm but may soften during urate-lowering therapy. Depending on their location, tophi may restrict joint mobility.
 

Gout is also often associated with multiple comorbidities, including hypertension, obesity, cardiovascular disease, diabetes, dyslipidemia, chronic kidney disease, and kidney stones. These comorbidities can complicate gout management and increase the risk of premature death.

 

▉Acute Gout Flares: Early Anti-inflammatory Treatment

 

For asymptomatic hyperuricemia, preventive measures such as dietary modification and weight loss should be considered. Urate-lowering drugs or anti-inflammatory agents are not currently recommended for gout prevention in this population.

 
Once an acute gout flare occurs, early anti-inflammatory treatment is recommended. The focus of treatment is pain control and suppression of joint inflammation. First-line therapies include oral corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), or colchicine.
 
The choice of drug depends on individual patient factors, including comorbidities, concomitant medications, and prior treatment efficacy and side effects.

  • NSAIDs should be avoided in patients with kidney disease, heart disease, peptic ulcer disease, or those taking anticoagulants.

  • High-dose oral prednisone should be avoided in the setting of infection, fluid retention, or diabetes.

  • Colchicine can be toxic in patients with severe kidney disease, severe liver disease, or those concurrently using ABCB1 inhibitors or CYP3A4 inhibitors (e.g., cyclosporine, ketoconazole, clarithromycin, and verapamil).

 

Additionally, clinical trials have shown:

  • Oral prednisolone, NSAIDs (including non-selective or COX-2 selective drugs), and low-dose colchicine have comparable efficacy for acute gout flares.

  • However, oral corticosteroids may have a better safety profile than NSAIDs, and NSAIDs have fewer side effects than low-dose colchicine.

  • Low-dose colchicine (1.0–1.2 mg immediately, followed by 0.5–0.6 mg one hour later) has comparable efficacy to high-dose colchicine (4.8 mg over 6 hours) but with fewer side effects. High-dose colchicine is not recommended.

 

For patients with gout flares who cannot take oral medications, intra-articular, intramuscular, or intravenous corticosteroids are an option. IL-1 inhibitors are reserved for patients who cannot tolerate or have contraindications to first-line anti-inflammatory treatments.
 
Non-pharmacological measures such as ice application can provide analgesic effects. Supportive care includes rest, mobility aids, and adequate nutrition and hydration.
 

At the same time, all patients experiencing a gout flare need to be informed about long-term effective urate-lowering therapy to prevent recurrence and joint damage.

 

▉Long-term Continuous Treatment to Achieve and Maintain Target Urate Levels

 

The main strategy for effective long-term gout management is a treat-to-target approach for serum urate, achieving sustained urate reduction to dissolve urate crystals. Clinical trials have demonstrated that this treatment strategy reduces gout flares, resolves tophi, and prevents joint damage in the long term.

 

For most patients with gout, the target serum urate level should be below 360 μmol/L. For those with a high urate burden (e.g., those with existing tophi), a more stringent target of ≤300 μmol/L is recommended.

 

 

When is urate-lowering therapy indicated?

 

Urate-lowering therapy is generally recommended for patients with:

  • Tophi, imaging evidence of joint damage due to gout, frequent gout flares (≥2 per year), or urolithiasis;

  • Younger patients (<40 years) with very high serum urate concentrations (>480 μmol/L) or comorbidities (kidney or heart disease).

 

Urate-lowering therapy can be initiated during a gout flare, starting with a low dose and gradually titrating upward.
 

During this period, low-dose anti-inflammatory drugs can be used to prevent gout flares (e.g., naproxen 250 mg daily, or colchicine 0.6 mg daily, for 3–6 months).

 

Choice of Urate-Lowering Drugs

 

For most patients with gout, allopurinol is the first-line urate-lowering therapy. Most patients can achieve target serum urate levels with allopurinol monotherapy. Allopurinol is generally well tolerated, though 1–2% of patients develop a rash requiring discontinuation. Allopurinol hypersensitivity syndrome is more common in carriers of the HLA-B*5801 allele (including some Asian and African American populations) and can be avoided through pre-screening.
 
Febuxostat is recommended as second-line urate-lowering therapy. Large trials have not reached consistent conclusions regarding febuxostat's cardiovascular risk. For patients who do not respond to or cannot tolerate allopurinol, physicians may recommend febuxostat while also monitoring cardiovascular risk.
 

Additionally, uricosuric agents such as probenecid and benzbromarone can promote urate excretion and may be used as monotherapy or in combination with allopurinol. However, a potential side effect is the risk of urolithiasis. Pegloticase metabolizes urate and has been shown in clinical trials to improve gout flares and tophi.

 

▉Long-term Gout Management: Addressing Comorbidities and Diet

 
Management of Comorbidities
 
Management of comorbidities is also crucial, including monitoring body mass index, blood pressure, creatinine, and glycated hemoglobin levels.
 
Some medications used to treat other conditions, such as the antihypertensive losartan, the SGLT-2 inhibitor class of glucose-lowering drugs, and the lipid-lowering agent fenofibrate, also have urate-lowering properties.
 
Dietary Modification
 

The DASH (Dietary Approaches to Stop Hypertension) diet and weight loss can help achieve modest reductions in serum urate levels.

DASH Diet: Emphasizes low fat, low salt, and low sugar, providing balanced nutrition. It recommends lean meats, poultry, and fish as primary protein sources, along with balanced intake of fruits, vegetables, dairy, whole grains, legumes, nuts, and limited fats and sweets; it also reduces salt and saturated fat intake, such as consuming low-fat milk and avoiding fatty meats.

 

Additionally, sugar-sweetened beverages and excessive alcohol (especially purine-rich beer) should be avoided. Purine-rich foods such as red meat and seafood also increase serum urate concentrations and the risk of gout.
 

Patients may benefit from identifying specific foods that trigger their gout flares and avoiding those dietary triggers. However, most patients cannot achieve target serum urate levels through dietary management alone.

 

▉Summary

Gout is common but treatable. Long-term urate lowering, particularly with medications such as allopurinol, can prevent gout flares and improve patients' quality of life. Through appropriate initiation and persistence of urate-lowering therapy, high-quality gout management can help improve patient outcomes.

Previous：13 Latest Proposals for the Pharmaceutical Industry at the 2

Back to List

Next：Can Two Doses of COVID-19 Vaccines Be from Different Brands?